Identification of exacerbations in obstructive lung disease through biomarkers

Biomarkers

Volumn 14, Issue 7, 2009, Pages 523-528

  Velthove, Karin J ^a,b   Bracke, Madelon ^a,b,c   Souverein, Patrick C ^a   Schweizer, René C ^b   Ten Berg, Maarten J ^a,b   Leufkens, Hubert G M ^a   Van Solinge, Wouter W ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c XPand Biotechnology BV   (Netherlands)

Author keywords

Eosinophil; Exacerbation; Hospital admission; Molecular epidemiology; Neutrophil; Obstructive lung disease

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; GLUCOCORTICOID;

AGED; ARTICLE; ASTHMA; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHILIA; OUTPATIENT DEPARTMENT;

ADULT; AGED; ASTHMA; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EOSINOPHILIA; EOSINOPHILS; FEMALE; HOSPITALIZATION; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; ODDS RATIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 70449380989     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547500903150763     Document Type: Article

References (33)

1. Andenaes R, Kalfoss MH. (2004). Psychological distress in hospitalized patients with chronic obstructive pulmonary disease. Eur J Epidemiol 19:851-859 (Pubitemid 41184410)
2. Anonymous. (2007). ATC Classification index with DDDs 2007. Nydalen: WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health.
3. Baibergenova A, Thabane L, Akhtar-Danesh N, Levine M, Gafni A, Moineddin R, Pulcins I. (2005). Effect of gender, age, and severity of asthma attack on patterns of emergency department visits due to asthma by month and day of the week. Eur J Epidemiol 20:947-956
4. Barnes P, Adcock I. (2003). How do corticosteroids work in asthma? Ann Intern Med 139:359-370
5. Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95.
6. Blais L, Ernst P, Boivin JF, Suissa S. (1998). Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med 158:126-132 (Pubitemid 28337169)
7. Blais L, Lemiere C, Menzies D, Berbiche D. (2006). Validity of asthma diagnoses recorded in the Medical Services database of Quebec. Pharmacoepidemiol Drug Saf 15:245-252
8. Boyter AC, Steinke DT. (2005). Changes in prescribing of inhaled corticosteroids (1999-2002) in Scotland. Pharmacoepidemiol Drug Saf 14:203-209
9. Califf RM, Ginsburg GS. (2008). Organizational improvements to enhance modern clinical epidemiology. JAMA 300:2300-2302
10. Chakraborty A, Blum RA, Cutler DL, Jusko WJ. (1999). Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers. Clin Pharmacol Ther 65:304-318 (Pubitemid 29142937)
11. Cho H, Kim JH. (2009). Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumour marker for cervical cancer. Biomarkers 14:161-170
12. Chung K, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, Bel E, Burney P, Chanez P, Connett G, Corrigan C, De Blic J, Fabbri L, Holgate S, Ind P, Joos G, Kerstjens H, Leuenberger P, Lofdahl C-G, McKenzie S, Magnussen H, Postma D, Saetta M, Salmeron S, Silverman M, Sterk P. (1999). Difficult/therapy-resistant asthma. The need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapyresistant asthma. Eur Respir J 13:1198-1208
13. Czock D, Keller F, Rasche F, Haussler U. (2005). Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61-98.
14. Douwes J, Gibson P, Pekkanen J, Pearce N. (2002). Non-eosinophilic asthma: importance and possible mechanisms. Thorax 57:643-648
15. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. (2006). Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 19:189-199
16. GINA. (2008). From the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). Available from: http://www.ginasthma.org [last accessed 13 July 2009].
17. GOLD. (2008). From the Global Strategy for the Diagnosis Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: http://www.goldcopd.org [last accessed 13 July 2009].
18. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. (2002). Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57:875-879
19. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung K, Barnes P. (1999). Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 160:1532-1539
20. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. (2000). The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 161:9-16.
21. Mahajan B, Vijayan VK, Agarwal MK, Bansal SK. (2008). Serum interleukin-1beta as a marker for differentiation of asthma and chronic obstructive pulmonary disease. Biomarkers 13:713-727
22. Movig KL, Leufkens HG, Lenderink AW, Egberts AC. (2003). Validity of hospital discharge International Classification of Diseases (ICD) codes for identifying patients with hyponatremia. J Clin Epidemiol 56:530-535
23. Pauwels RA. (2004). Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 1:73-76
24. Roede BM, Bresser P, Bindels PJ, Kok A, Prins M, ter Riet G, Geskus RB, Herings RM, Prins JM. (2008). Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: An historical population based cohort study. Thorax 63:968-973
25. Steele RW, Steele CR, Pilkington NS Jr, Charlton RK. (1987). Functional capacity of marginated and bone marrow reserve granulocytes. Infect Immun 55:2359-2363
26. Sutherland ER. (2004). Outpatient treatment of chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol 114:715-724
27. Ten Berg MJ, Huisman A, van den Bemt PM, Schobben AF, Egberts AC, van Solinge WW. (2007). Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med 45:13-19.
28. Valet G. (2006). Cytomics as a new potential for drug discovery. Drug Discov Today 11:785-791
29. Van Ganse E, van der Linden PD, Leufkens HG, Herings RM, Vincken W, Ernst P. (1995). Asthma medications and disease exacerbations: An epidemiological study as a method for asthma surveillance. Eur Respir J 8:1856-1860
30. Velthove KJ, van Solinge WW, Lammers JW, Leufkens HG, Schweizer RC, Bracke M. (2009). Hematocytometry analysis as discriminative marker for asthma phenotypes. Clin Chem Lab Med 47:573-578
31. Wenzel S, Fahy J, Irvin C, Peters S, Spector S, Szefler S. (2000). Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 162:2341-2351
32. Wild N, Karl J, Grunert VP, Schmitt RI, Garczarek U, Krause F, Hasler F, van Riel PL, Bayer PM, Thun M, Mattey DL, Sharif M, Zolg W. (2008). Diagnosis of rheumatoid arthritis: multivariate analysis of biomarkers. Biomarkers 13:88-105.
33. Zhang X, Moilanen E, Kankaanranta H. (2001). Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol 431:365-371